Levodopa News and Research

RSS

NeuroDerm enrolls patients for Phase IIa clinical trial of ND0612

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

16 Apr 2013

Parkinson's Disease drug can help reverse age-related impairments in decision making: Study

A drug widely used to treat Parkinson's Disease can help to reverse age-related impairments in decision making in some older people, a study from researchers at the Wellcome Trust Centre for Neuroimaging has shown.

25 Mar 2013

Columbia University Medical Center, NewYork-Presbyterian Hospital present research works at AAN meeting

The following research from Columbia University Medical Center and NewYork-Presbyterian Hospital is being presented at the 65th annual meeting of the American Academy of Neurology, March 16-23, 2013, in San Diego.

18 Mar 2013

Promising studies for Parkinson's to be presented at 65th AAN meeting

Three studies released today present possible positive news for people with Parkinson's disease. The studies, which will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013, report on treatments for blood pressure problems, the wearing-off that can occur when people have taken the main drug for Parkinson's for a long time, and for people early in the disease whose symptoms are not well-controlled by their main drugs.

15 Mar 2013

Phase III success with extended-release carbidopa–levodopa formulation

An extended-release formulation of carbidopa–levodopa reduces the amount of off-time in patients with Parkinson’s disease, show results from a phase III randomized trial.

5 Mar 2013

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease.

4 Mar 2013

Earlier may be better for neurostimulation in Parkinson’s

Adding neurostimulation to best medical therapy boosts quality of life in patients with relatively early-stage Parkinson’s disease, shows a randomized trial.

18 Feb 2013

STN confirmed as preferred stimulation target in Parkinson’s

Subthalamic nucleus stimulation is at worst equivalent and at best superior to globus pallidus pars interna stimulation in patients with Parkinson’s disease, shows a randomized trial.

22 Jan 2013

Researchers identify and test first blood-based circulating miRNA biomarkers for Parkinson's

Parkinson's disease (PD) is a progressive neurological condition. At present, it is usually diagnosed only when motor features are present. Hence, there is a need to develop objective and measurable biomarkers to improve PD diagnostics during its earlier stage, prior to its motor onset. In this pilot study, researchers identified and tested the first blood-based circulating microRNA (miRNA) biomarkers for PD.

21 Jan 2013

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

21 Nov 2012

Dopamine improves long-term memory

The feel-good hormone dopamine improves long-term memory. This is the finding of a team lead by Emrah D-zel, neuroscientist at the German Center for Neurodegenerative Diseases and the University of Magdeburg.

9 Nov 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012

Age, drugs, and disease alter sleep in Parkinson’s disease

Sleep patterns in patients with Parkinson’s disease are affected by age, disease severity, and dopamine agonists, German research indicates.

17 Aug 2012

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

A new delivery method for levodopa/carbidopa, a common dual-drug Parkinson's disease (PD) regimen, significantly improved the duration of the drugs' effectiveness in people with advanced PD, according to research by Mount Sinai School of Medicine.

21 Jun 2012

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Today Abbott announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease.

19 Jun 2012

Civitas commences CVT-301 Phase 2a trial in Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today the initiation of a Phase 2a clinical trial in Parkinson's disease patients evaluating CVT-301, an inhaled formulation of levodopa (L-dopa), for the rapid relief from motor fluctuations.

16 Jun 2012

Acute levodopa may worsen motor plasticity in late-stage PD

Administering acute doses of levodopa appears to worsen motor cortex plasticity as Parkinson’s disease advances, researchers report.

14 Jun 2012

Adamas to present update on Nurelin program at CHI Targeting Parkinson's Disease Symposium

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it will present an update on its Nurelin (amantadine HCl extended release capsules) program at the Cambridge Healthtech Institute's (CHI) Targeting Parkinson's Disease Symposium being held today in Philadelphia.

4 Jun 2012

LCIG improves quality of life, reduces symptoms of Parkinson's

A recent clinical trial conducted at Evergreen Healthcare shows that a new form of a common drug used to treat Parkinson's Disease greatly improves the quality of life for patients and reduces the affects of symptoms such as tremors, slowness, stiffness and difficulty walking.

21 Apr 2012

Impax announces data from IPX066 Phase III study on Parkinson's

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28.

19 Apr 2012